Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

(?-p-Cymene)bis-(trichlorido-stannyl)(triethoxy-phosphine-?P)ruthenium(II).

ABSTRACT: In the title complex, [RuSn(2)(C(10)H(14))Cl(6)(C(6)H(15)O(3)P)], the Ru-Sn bond lengths [2.5619?(3) and 2.5669?(3)?Å] are about 0.3?Å shorter than the sum of the covalent Ru and Sn radii (1.46 + 1.39 = 2.85?Å), in line with other structurally characterized arene ruthenium trichlorido-stannyl derivatives. The Ru(II) atom is surrounded by a para-cymene, a triethylphosphite and two trichloridostannyl ligands in a typical piano-stool coordination.

SUBMITTER: Shapovalov SS

PROVIDER: S-EPMC2971135 | biostudies-literature | 2009 Oct

REPOSITORIES: biostudies-literature

ACCESS DATA

Json Xml

Publications

(η-p-Cymene)bis-(trichlorido-stannyl)(triethoxy-phosphine-κP)ruthenium(II).

Shapovalov Sergey S SS Therrien Bruno B

Acta crystallographica. Section E, Structure reports online 20091023 Pt 11

In the title complex, [RuSn(2)(C(10)H(14))Cl(6)(C(6)H(15)O(3)P)], the Ru-Sn bond lengths [2.5619 (3) and 2.5669 (3) Å] are about 0.3 Å shorter than the sum of the covalent Ru and Sn radii (1.46 + 1.39 = 2.85 Å), in line with other structurally characterized arene ruthenium trichlorido-stannyl derivatives. The Ru(II) atom is surrounded by a para-cymene, a triethylphosphite and two trichloridostannyl ligands in a typical piano-stool coordination. ...[more]

PMID: 21578155

Similar Datasets

1,3-Bis(2-thienylmeth-yl)-4,5-dihydro-imidazolium trichlorido(?-p-cymene)ruthenate(II).

Project description:The asymmetric unit of the title compound, (C(13)H(15)N(2)S(2))[RuCl(3)(C(10)H(14))], contains a 1,3-(2-thienylmeth-yl)-4,5-dihydro-imidazolium cation and a trichlorido(?(6)-p-cymene)ruthenate(II) anion. The thio-phene rings of the cation are disordered by an 180° rotation about the thio-phene-CH(2) bonds with occupancies of 0.847?(5)/0.153?(5) and 0.700?(5)/0.300?(5), respectively. The Ru atom exhibits a distorted octa-hedral coordination with the benzene ring of the p-cymene ligand formally occupying three sites and three Cl atoms occupying the other three sites. The short C-N bond lengths in the imidazoline ring indicate partial electron delocalization within the N-C-N fragment. Cation and anions are connected through five inter-molecular C-H?Cl hydrogen bonds and one C-H?? hydrogen bond, forming a three-dimensional hydrogen-bonded network.

| S-EPMC2968218 | biostudies-literature

Tetra-ethyl-ammonium trichlorido(η-p-cymene)ruthenate(II).

Project description:In the title salt, [(C(2)H(5))(4)N][RuCl(3)(C(10)H(14))], the Ru(II) atom shows an octa-hedral coordination in which the aromatic ring of the p-cymene mol-ecule occupies three coordination positions.

| S-EPMC2971931 | biostudies-literature

1,3-Bis(thio-phen-2-ylmeth-yl)-3,4,5,6-tetra-hydro-pyrimidinium trichlorido(?-p-cymene)ruthenate(II).

Project description:The asymmetric unit of the title compound, (C(14)H(17)N(2)S(2))[Ru(C(10)H(14))Cl(3)], contains a 1,3-bis-(thio-phen-2-ylmeth-yl)-3,4,5,6-tetra-hydro-pyrimidinium cation and a trichlorido(?(6)-p-cymene)ruthenate(II) anion. The Ru atom exhibits a distorted octa-hedral coordination with the benzene ring of the p-cymene ligand formally occupying three sites and three chloride atoms occupying the other three sites. The N-C bond lengths of the N-C-N unit of the pyrimidinium cation are shorter than the average single C-N bond length of 1.48?Å, thus showing double-bond character, indicating a partial electron delocalization within the N-C-N fragment. The pyrimidine ring has an envelope conformation. Four inter-molecular C-H?Cl hydrogen bonds generate a three-dimensional hydrogen-bonded framework.

| S-EPMC2968014 | biostudies-literature

μ-Pyrazine-2,5-dicarboxyl-ato-bis-[chlorido(η-p-cymene)ruthenium(II)] tert-butanol disolvate.

Project description:A new tert-butanol solvate of [{((i)PrC(6)H(4)Me)RuCl}(2){μ-2,5-pyz(COO)(2)}] (pyz = pyrazine) has been crystallized and structurally characterized. The solvate, [Ru(2)(C(10)H(14))(2)(C(6)H(2)N(2)O(4))Cl(2)]·2C(4)H(10)O, contains one half-mol-ecule of the ruthenium(II) complex and one mol-ecule of tert-butanol in the asymmetric unit. The complex mol-ecule lies on an inversion centre with the two chlorides trans. In contrast, the previously reported structure was solvent-free. Similar metric parameters are found between the butanol solvate and the solvent-free form and an inter-molecular O-H⋯O hydrogen bond exists between μ-pyrazine-2,5-dicarboxyl-ato-bis-[chlorido(η(6)-p-cymene)-ruthenium(II)] and the tert-butanol mol-ecule.

| S-EPMC2960433 | biostudies-literature

Dichlorido(?-p-cymene)(4-fluoro-aniline-?N)ruthenium(II).

Project description:The title compound, [RuCl(2)(C(10)H(14))(C(6)H(6)FN)], a pseudo-octa-hedral d(6) complex, has the expected piano-stool geometry around the Ru(II) atom. The fluoro-aniline ring forms a dihedral angle of 19.3?(2)° with the p-cymene ring. In the crystal, two mol-ecules form an inversion dimer via a pair of N-H?Cl hydrogen bonds. Weak inter-molecular C-H?Cl inter-actions involving the p-cymene ring consolidate the crystal packing.

| S-EPMC3050405 | biostudies-literature

p-Cymene Complexes of Ruthenium(II) as Antitumor Agents.

Project description:In this work, the cytotoxic behavior of six ruthenium(II) complexes of stoichiometry [(η6-p-cymene)RuCl2L] (I-VI), L = 4-cyanopyridine (I), 2-aminophenol (II), 4-aminophenol (III), pyridazine (IV), and [(η6-p-cymene)RuClL2]PF6; L = cyanopyridine (V), L = 2-aminophenol(VI) towards three cell lines was studied. Two of them, HeLa and MCF-7, are human carcinogenic cells from cervical carcinoma and human breast cancer, respectively. A comparison with healthy cells was carried out with BGM cells which are monkey epithelial cells of renal origin. The behavior of complex II exhibits selectivity towards healthy cells, which is a promising feature for use in cancer treatment since it might reduce the side effects of most current therapies.

| S-EPMC7662397 | biostudies-literature

cis-cis-trans-Bis(acetonitrile-κN)dichloridobis(triphenyl-phosphine-κP)ruthenium(II) acetonitrile disolvate.

Project description:The title compound, [RuCl(2)(C(2)H(3)N)(2)(C(18)H(15)P)(2)]·2C(2)H(3)N, was obtained upon stirring an acetonitrile/ethanol solution of [RuCl(2)(PPh(3))(3)]. In the crystal structure, each Ru(II) ion is coordinated by two Cl [Ru-Cl = 2.4308 (7) and 2.4139 (7) Å], two N [Ru-N = 2.016 (2) and 2.003 (2) Å], and two P [Ru-P = 2.3688 (7) and 2.3887 (7) Å] atoms in a distorted octa-hedral geometry. Packing inter-actions include typical C-H⋯π contacts involving phenyl groups as well as weak hydrogen bonds between CH(3)CN methyl H atoms and Cl or solvent CH(3)CN N atoms.

| S-EPMC2915117 | biostudies-literature

Tuning the Cytotoxicity of Bis-Phosphino-Amines Ruthenium(II) Para-Cymene Complexes for Clinical Development in Breast Cancer.

Project description:Despite some limitations such as long-term side effects or the potential presence of intrinsic or acquired resistance, platinum compounds are key therapeutic components for the treatment of several solid tumors. To overcome these limitations, maintaining the same efficacy, organometallic ruthenium(II) compounds have been proposed as a viable alternative to platinum agents as they have a more favorable toxicity profile and represent an ideal template for both, high-throughput and rational drug design. To support the preclinical development of bis-phoshino-amine ruthenium compounds in the treatment of breast cancer, we carried out chemical modifications in the structure of these derivatives with the aim of designing less toxic and more efficient therapeutic agents. We report new bis-phoshino-amine ligands and the synthesis of their ruthenium counterparts. The novel ligands and compounds were fully characterized, water stability analyzed, and their in vitro cytotoxicity against a panel of tumor cell lines representative of different breast cancer subtypes was evaluated. The mechanism of action of the lead compound of the series was explored. In vivo toxicity was also assessed. The results obtained in this article might pave the way for the clinical development of these compounds in breast cancer therapy.

| S-EPMC8539368 | biostudies-literature

(?-Cyclo-penta-dien-yl)(propionitrile-?N)bis-(triphenyl-phosphine-?P)ruthenium(II) trifluoro-methane-sulfonate.

Project description:The title compound, [Ru(C(5)H(5))(C(3)H(5)N)(C(18)H(15)P)(2)]CF(3)SO(3), forms yellow crystals with a distinctly hemimorphic habit. It contains a half-sandwich complex of ruthenium with a three-legged piano-stool geometry, with Ru-P = 2.3585?(4) and 2.3312?(4)?Å, and Ru-N = 2.0422?(15)?Å?as the legs. The CF(3)SO(3) (-) anion is anchored in the crystal lattice by C-H?O and C-H?F hydrogen bonds, with C?F,O distances starting at 3.125?(2)?Å.

| S-EPMC2971339 | biostudies-literature

Dichlorido(?(6)-p-cymene)(eth-oxy-diphenyl-phosphane)ruthenium(II).

Project description:The title compound, [RuCl2(C10H14)(C14H15OP)], is an Ru(II) complex in which an ?(6)-p-cymene ligand, two chloride anions and the P atom of an ethoxydiphenylphosphane ligand form a piano-stool coordination environment about the central Ru(II) atom.

| S-EPMC3588727 | biostudies-literature

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data